FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

Daily Current Affairs / FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

Change Language English Hindi

Category : Science and Tech Published on: June 21 2025

Share on facebook

The U.S. FDA has approved injectable lenacapavir as a semiannual HIV prevention method. This follows positive outcomes from PURPOSE 1 & 2 clinical trials in 2024. The WHO welcomed the move, highlighting it as a significant step in expanding HIV prevention options with a long-acting, convenient alternative for vulnerable populations.

Jul 19

Jul 19

Jul 19

Jul 18

Jul 18

FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

Recent Post's

Notification view all

Jul 19

Jul 19

Jul 19

Jul 18

Jul 18

FDA Approves Injectable Lenacapavir as Long-Acting HIV Prevention Option:

Recent Post's

Notification
view all